ATE263563T1 - Mittel gegen juckreiz - Google Patents

Mittel gegen juckreiz

Info

Publication number
ATE263563T1
ATE263563T1 AT03001740T AT03001740T ATE263563T1 AT E263563 T1 ATE263563 T1 AT E263563T1 AT 03001740 T AT03001740 T AT 03001740T AT 03001740 T AT03001740 T AT 03001740T AT E263563 T1 ATE263563 T1 AT E263563T1
Authority
AT
Austria
Prior art keywords
remedies
itching
morphinian
antipruritic
opiate
Prior art date
Application number
AT03001740T
Other languages
English (en)
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Kuniaki Kawamura
Junzo Kamei
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE263563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE263563T1 publication Critical patent/ATE263563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Table Equipment (AREA)
  • Elimination Of Static Electricity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Magnetic Record Carriers (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03001740T 1996-11-25 1997-11-21 Mittel gegen juckreiz ATE263563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25

Publications (1)

Publication Number Publication Date
ATE263563T1 true ATE263563T1 (de) 2004-04-15

Family

ID=18041771

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03001740T ATE263563T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT97912539T ATE359076T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT97912539T ATE359076T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Country Status (15)

Country Link
US (2) US6174891B1 (de)
EP (5) EP1310255B1 (de)
KR (1) KR100557801B1 (de)
CN (3) CN1180844C (de)
AT (3) ATE263563T1 (de)
AU (1) AU738743B2 (de)
CA (1) CA2244256C (de)
DE (3) DE69732868T2 (de)
DK (1) DK0897726T3 (de)
ES (3) ES2285733T3 (de)
NO (1) NO316309B1 (de)
NZ (1) NZ331001A (de)
PT (1) PT897726E (de)
TW (1) TW542838B (de)
WO (1) WO1998023290A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
ATE384532T1 (de) * 1996-12-24 2008-02-15 Elkhoury George F Topische anwendung von opioiden, wie morphin, zur linderung von juckreiz und hautkrankheiten sowie hautreizungen
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
CN1204139C (zh) 1999-08-24 2005-06-01 东丽株式会社 神经性疼痛治疗剂
WO2001074819A1 (en) * 2000-04-03 2001-10-11 Toray Industries, Inc. Analgesics containing morphinan n-oxide derivatives as the active ingredient
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
US8338442B2 (en) 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
JP4239592B2 (ja) * 2001-05-08 2009-03-18 東レ株式会社 敗血症治療剤
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
EP1450824A4 (de) * 2001-11-02 2005-09-28 Elan Corp Plc Pharmazeutische zusammensetzung
KR101035931B1 (ko) 2002-03-29 2011-05-23 산텐 세이야꾸 가부시키가이샤 2-페닐벤조티아졸린 유도체로 이루어진 κ 오피오이드 수용체 작용약
EP1551402A4 (de) * 2002-09-23 2009-05-27 Verion Inc Gegen missbrauch gesicherte pharmazeutische zusammensetzungen
PT1543010E (pt) * 2002-09-25 2007-07-26 Euro Celtique Sa Hidromorfonas n-substituídas e a sua utilização
TW200533355A (en) 2004-03-30 2005-10-16 Toray Industries Antipruritic agent
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
AU2006221314B2 (en) * 2005-03-10 2012-09-06 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis
WO2006109671A1 (ja) * 2005-04-06 2006-10-19 Toray Industries, Inc. モルヒナン誘導体の結晶及びその製造法
WO2007055184A1 (ja) * 2005-11-09 2007-05-18 Toray Industries, Inc. 機能性腸障害の治療または予防剤
WO2007072749A1 (ja) * 2005-12-21 2007-06-28 Toray Industries, Inc. 鎮咳剤
EP2099764B1 (de) * 2006-09-20 2011-07-27 Mallinckrodt Inc. Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2137189B1 (de) * 2007-03-06 2015-05-06 Mallinckrodt LLC Verfahren zur herstellung quaternärer n-alkyl-morphinin-alkaloid-derivate
PL2151240T3 (pl) 2007-04-24 2014-01-31 Toray Industries Środek terapeutyczny lub profilaktyczny przeciw dyskinezie
PT2151241E (pt) 2007-04-26 2012-05-07 Toray Industries Preparação sólida estável compreendendo um derivado de 4,5-epoximorfinano
EP2168580B1 (de) 2007-06-22 2015-12-02 Toray Industries, Inc. Heilmittel oder prophylaktikum für schizophrenie
PL2196206T3 (pl) * 2007-10-05 2020-02-28 Toray Industries, Inc. Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
US8148528B2 (en) * 2008-05-27 2012-04-03 Mallinckrodt Llc Processes and compounds for the preparation of normorphinans
EP2331508B1 (de) 2008-09-03 2014-11-12 Mallinckrodt LLC Substituierte berbine und verfahren zu ihrer synthese
CN102325776A (zh) * 2009-02-23 2012-01-18 马林克罗特公司 (+)-吗啡喃*季盐及其制备方法
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8563724B2 (en) * 2009-02-23 2013-10-22 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
EP2398806A1 (de) * 2009-02-23 2011-12-28 Mallinckrodt LLC (+)-morphinanium-n-oxide und verfahren zu ihrer herstellung
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PH12012501552A1 (en) 2010-01-29 2017-04-26 Toray Industries Therapeutic or prophylactic agent for biliary diseases
CA2825165C (en) 2011-01-31 2018-07-03 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
MX2014002630A (es) 2011-09-08 2014-04-14 Mallinckrodt Llc Produccion de alcaloides sin el aislamiento de compuestos intermediarios.
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
JPWO2016052617A1 (ja) * 2014-09-30 2017-09-21 国立大学法人 筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
CN109310656A (zh) * 2016-03-21 2019-02-05 特雷维治疗股份有限公司 尿毒症性瘙痒症的治疗
WO2018103624A1 (zh) * 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
DK3761982T3 (da) 2018-03-08 2025-01-02 Victoria Link Ltd Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
AU2020250468A1 (en) * 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
TWI893157B (zh) 2020-06-30 2025-08-11 日商東麗股份有限公司 具有嗎啡喃骨架之化合物或其藥理學上可容許之酸加成鹽的用途
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
WO2025095039A1 (ja) * 2023-10-31 2025-05-08 ティア・リサーチ・コンサルティング合同会社 皮膚疾患の医薬組成物、及び医薬品の新規用途探索方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
CA2017020A1 (en) * 1989-05-18 1990-11-18 Alan Naylor Chemical compounds
ES2121988T3 (es) * 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
CN1111900A (zh) * 1993-06-30 1995-11-15 东丽株式会社 止咳药
PL314036A1 (en) * 1993-10-20 1996-08-05 Boots Co Plc Pharmaceutical composition
IT1273751B (it) * 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
CN1214634A (zh) 1999-04-21
CA2244256C (en) 2006-07-11
NZ331001A (en) 2000-05-26
AU738743B2 (en) 2001-09-27
US6316461B1 (en) 2001-11-13
CN1291717C (zh) 2006-12-27
PT897726E (pt) 2007-07-09
CA2244256A1 (en) 1998-06-04
EP1310255B1 (de) 2004-04-07
EP1327444A1 (de) 2003-07-16
ATE359076T1 (de) 2007-05-15
EP0897726A1 (de) 1999-02-24
EP0897726A4 (de) 2003-05-28
CN1530111A (zh) 2004-09-22
CN1535687A (zh) 2004-10-13
EP1310251A1 (de) 2003-05-14
DE69728585T2 (de) 2004-08-05
EP1327444B1 (de) 2005-03-23
ATE291429T1 (de) 2005-04-15
JP3531170B2 (ja) 2004-05-24
ES2215158T3 (es) 2004-10-01
NO983431L (no) 1998-09-24
EP0897726B1 (de) 2007-04-11
DE69728585D1 (de) 2004-05-13
ES2236630T3 (es) 2005-07-16
KR19990081978A (ko) 1999-11-15
US6174891B1 (en) 2001-01-16
EP1310255A1 (de) 2003-05-14
DE69732868D1 (de) 2005-04-28
ES2285733T3 (es) 2007-11-16
TW542838B (en) 2003-07-21
DE69737592T2 (de) 2008-01-03
EP1312361A1 (de) 2003-05-21
WO1998023290A1 (en) 1998-06-04
DE69737592D1 (de) 2007-05-24
KR100557801B1 (ko) 2006-04-21
CN1180844C (zh) 2004-12-22
NO316309B1 (no) 2004-01-12
AU4968397A (en) 1998-06-22
DE69732868T2 (de) 2006-04-13
DK0897726T3 (da) 2007-08-13
NO983431D0 (no) 1998-07-24

Similar Documents

Publication Publication Date Title
ATE291429T1 (de) Mittel gegen juckreiz
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ID18883A (id) Pesaing 5-ht 1f
ATE199552T1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE69928655D1 (de) Substituierte porphyrine
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
IT1285770B1 (it) Composti corticoidei
PT1117403E (pt) Antagonistas de mglurs para o tratamento da dor e ansiedade
EA199900912A1 (ru) Фармацевтические средства
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
EA200000522A1 (ru) 5-htагонисты
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
NO20005548D0 (no) Mykobakterieinhibitorer
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties